Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
196
Stocks News & Analysis
stocks
Investors overly concerned about AI impact on ASX share
Shares screen as undervalued after prolonged decline.
stocks
After earnings, is Palantir stock a buy, a sell, or fairly valued?
With higher-than-expected revenue expectations and a raised fair value estimate, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,156.70 | 17.70 | -0.19% |
| CAC 40 | 8,323.28 | 49.44 | 0.60% |
| DAX 40 | 25,014.87 | 293.41 | 1.19% |
| Dow JONES (US) | 50,135.87 | 20.20 | 0.04% |
| FTSE 100 | 10,386.23 | 16.48 | 0.16% |
| HKSE | 27,167.18 | 140.02 | 0.52% |
| NASDAQ | 23,238.67 | 207.46 | 0.90% |
| Nikkei 225 | 57,712.18 | 1,348.24 | 2.39% |
| NZX 50 Index | 13,513.68 | 67.31 | 0.50% |
| S&P 500 | 6,964.82 | 32.52 | 0.47% |
| S&P/ASX 200 | 8,886.40 | 25.20 | -0.28% |
| SSE Composite Index | 4,124.87 | 1.78 | 0.04% |